Loading…

Fetal growth restriction: Case definition & guidelines for data collection, analysis, and presentation of immunization safety data

Preamble Need for developing case definitions and guidelines for data collection, analysis, and presentation for fetal growth restriction as an adverse event following immunization Fetuses that fail to meet their growth potential in utero are at risk for adverse antenatal and postnatal events such a...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2017-12, Vol.35 (48), p.6546-6554
Main Authors: Easter, Sarah Rae, Eckert, Linda O., Boghossian, Nansi, Spencer, Rebecca, Oteng-Ntim, Eugene, Ioannou, Christos, Patwardhan, Manasi, Harrison, Margo S., Khalil, Asma, Gravett, Michael, Goldenberg, Robert, McKelvey, Alastair, Gupta, Manish, Pool, Vitali, Robson, Stephen C., Joshi, Jyoti, Kochhar, Sonali, McElrath, Tom
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Preamble Need for developing case definitions and guidelines for data collection, analysis, and presentation for fetal growth restriction as an adverse event following immunization Fetuses that fail to meet their growth potential in utero are at risk for adverse antenatal and postnatal events such as stillbirth, preterm birth, and adverse neonatal and long-term health outcomes [1-5]. [...]antenatal recognition and monitoring of fetal growth restriction (FGR) is an important component of prenatal care [6-8]. [...]the Brighton case definition of FGR will focus on use of a combination of B-mode and Doppler ultrasound technology to establish the diagnosis of FGR. [...]to avoid selection bias, a restrictive time interval from immunization to onset of FGR should not be an integral part of such a definition. [...]we would like to acknowledge the Global Alignment of Immunization Safety Assessment in Pregnancy (GAIA) project, funded by the Bill and Melinda Gates Foundation.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2017.01.042